Novartis and Orionis strike second molecular glue deal for $40M upfront

From L-R: Orionis chief strategy officer Giulio Draetta, CEO Niko Kley and chief data scientist Riccardo Sabatini June 10, 2026 11:34 AM EDT DealsPharma No­var­tis and Ori­o­n­is strike sec­ond mol­e­c­u­lar glue deal for $40M up­front Kyle LaHucik Biotech Correspondent No­var­tis is dou­bling down on its part­ner­ship with Ori­o­n­is Bio­sciences in a deal worth $40 mil­lion up­front and up to $1.4 … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER